Shares of Sarepta Therapeutics (SRPT -2.4%) fall for a second day and are now down ~6% since...

Shares of Sarepta Therapeutics (SRPT -2.4%) fall for a second day and are now down ~6% since late Thursday after comments from CEO Chris Garabedian at the dbAccess Health Care Conference (transcript) fail to inspire confidence regarding regulatory progress for the company's muscular dystrophy program. "It looks like the meeting that we were hoping to have calendered by the end of June [will] be calendered in Q3 based on [the FDA's] scheduling," Garabedian says, referring to the application for accelerated approval of eteplirsen (I, II, III).